Global Partners L.P. (GLP)
NYSE NYSE Primary 
Hims & Hers: Bargain EBITDA Multiples As GLP-1 Drama Passes
Hims & Hers has sharply declined, losing nearly 40% YTD and two-thirds from last year's peak. Despite the selloff, I see compelling value in HIMS at its current, compressed valuation. Markets have penalized the stock for its expectation of slight adjusted EBITDA margin contraction in FY26, which is due to its expansion into new markets (Europe and Japan). The company's $1.15 billion acquisition of Eucalyptus (closing mid-2026) jumpstarts its international push, and lays the foundation for the company to scale to profitability overseas.
Albertsons cites slower GLP-1 growth, higher gas prices for a sales miss and downbeat outlook
Albertsons's stock was falling Tuesday after a sales miss and an announcement that the grocery-store chain has reached a $774 million settlement to resolve opioid-related claims.
Are Investors Undervaluing Global Partners (GLP) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Novo Nordisk: Intense Competition Within The GLP-1 Duopoly
Novo Nordisk reached an all-time high of $148.15 in June 2024, when market participants were widely optimistic about the prospects of NVO's new semaglutide drug for weight management, Wegovy. After a long series of disappointments and missteps, Novo Nordisk closed at $37.98 per share as of April 13th, the equivalent of a ~75% drawdown in less than 24 months. Even though market expectations have been revised lower multiple times, Novo Nordisk continues to generate a significant amount of free cash flow while being supported by a strong 'AA' balance sheet.
GLP-1 giant Novo Nordisk partners with OpenAI as pharma industry's AI race accelerates
The Danish drugmaker becomes the latest major pharmaceutical company to embed AI across its entire drug development pipeline, from discovery to commercial operations. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant best known for its diabetes and obesity treatments, has formed a partnership with OpenAI that will apply the artificial intelligence company's most advanced capabilities.
Novo Nordisk's GLP-1 pill momentum faces pricing test, says leading bank
Novo Nordisk (NYSE:NVO) reports first-quarter 2026 results on 6 May, with UBS flagging that the results will provide the first meaningful look at the company's economics at new, lower price points for its GLP-1 (glucagon-like peptide-1) obesity and diabetes drugs. The Danish pharmaceutical company has shed 27% of its market value year to date, hit by full-year 2026 guidance that came in significantly below market expectations and a disappointing clinical trial readout for CagriSema, a combination drug that proved inferior to rival Eli Lilly's Zepbound in the REDEFINE-4 study.
Oral GLP-1 Is Here - Have Credit Markets Caught Up?
For the past two years, GLP-1 medications have been a fixture of consumer trend analysis, discussed by everyone from CNBC to sell-side strategists to management consultants. Real apparel expenditure outperformed total consumer spending by approximately 400 basis points per month on average in 2025, a trend our analysis attributes in part to GLP-1-driven wardrobe replacement. The oral pill launch likely means the population of GLP-1 users will grow materially over the next several years.
Hims & Hers price target slashed amid GLP-1 transition
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-term earnings pressures. Shares of Hims & Hers traded hands at about $20 on Wednesday, down almost 39% so far this year.
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.
Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results
Kailera Therapeutics is targeting an IPO to fund GLP-1-based obesity treatments, led by ribupatide, with positive efficacy data versus tirzepatide. KLRA is well-capitalized with $546 million in cash, strong investor backing, and an experienced management team, positioning it for extensive clinical development. Ribupatide demonstrated a 23.6% mean weight reduction over 12 weeks at 8 mg in late-stage trials, outpacing placebo and suggesting competitive differentiation.
I'm Watching These 6 Dividend Stocks For Big Announcements
Dividend raises mean something right now.
Bank of America sees Eli Lilly's Foundayo as preferred oral GLP-1
Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy Foundayo, a move Bank of America says could expand the obesity market without cannibalizing the company's existing Zepbound product. In a note to clients, Bank of America reiterated its Buy rating on Lilly, citing the early approval and favorable labeling of Foundayo, also known as orforglipron.
